Elixiron (ELIX) Reports Phase 2 Interim Data for Alzheimer's Drug

Elixiron (ELIX) has announced interim data from its Phase 2 clinical trial for a new Alzheimer's drug. The data included specific results indicating a 30% improvement in cognitive function among participants compared to the placebo group. The company expects to submit these results for regulatory review in Q1 2024. This development is significant as it may impact Elixiron's market valuation and investor interest in biotech companies focusing on Alzheimer's treatments.